1 ASSESSING THE RELATIONSHIP BETWEEN MONOALLELIC PARK2 MUTATIONS AND PARKINSON'S

2 **RISK**

3

4 AUTHORSHIP

- 5 Steven J Lubbe¹; Bernabe Bustos¹; Jing Hu¹; Dimitri Krainc¹; Theresita Joseph²; Jason Hehir³; Manuela
- 6 Tan²; Weijia Zhang²; Valentina Escott-Price⁴; Nigel M Williams⁴; Cornelis Blauwendraat⁵; Andrew B
- ⁷ Singleton⁵; Huw R Morris^{2*} for International Parkinson's Disease Genomics Consortium (IPDGC)⁶.
- 8
- 1 Ken and Ruth Davee Department of Neurology, and Simpson Querrey Center for Neurogenetics,
- 10 Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
- 11 2 Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology,
- 12 University College London, London, UK and UCL Movement Disorders Centre, UCL Queen Square
- 13 Institute of Neurology
- 14 3 National Hospital for Neurology and Neurosurgery, Queens Square, London, UK
- 4 Institute of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre
- 16 for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology,
- 17 Cardiff University School of Medicine, Cardiff, UK
- 18 5 Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National
- 19 Institutes of Health, Bethesda, Maryland, USA
- 20 6 See https://pdgenetics.org/partners

21 CORRESPONDING AUTHOR

- 22 Professor Huw R. Morris
- 23 Department of Clinical and Movement Neuroscience, UCL Institute of Neurology, London, NW3 2PF,
- 24 United Kingdom.
- 25 Email: h.morris@ucl.ac.uk
- ²⁶ Telephone: +44 (0)20 7830 2951

27 ABSTRACT

Biallelic PARK2 (Parkin) mutations cause autosomal recessive Parkinson's (PD); however, the role of 28 monoallelic PARK2 mutations as a risk factor for PD remains unclear. We investigated the role of 29 single heterozygous PARK2 mutations in three large independent case-control cohorts totalling 30 10,858 PD cases and 8,328 controls. Overall, after exclusion of biallelic carriers, single PARK2 31 mutations were more common in PD than controls conferring a >1.5-fold increase in risk of PD 32 (P=0.035), with meta-analysis (19,574 PD cases and 468,488 controls) confirming increased risk 33 (OR=1.65, P=3.69E-07). Carriers were shown to have significantly younger ages at onset compared to 34 non-carriers (NeuroX: 56.4 vs. 61.4 years; Exome: 38.5 vs. 43.1 years). Stratifying by mutation type, 35 36 we provide preliminary evidence for a more pathogenic risk profile for single PARK2 copy number variant (CNV) carriers compared to single nucleotide variant carriers. Studies that did not assess 37 biallelic PARK2 mutations or consist of predominantly early-onset cases may be biasing these 38 estimates, and removal of these resulted in a loss of association (OR=1.23, P=0.614; n=4). 39 Importantly, when we looked for additional CNVs in 30% of PD cases with apparent monoallellic 40 PARK2 mutations we found that 44% had biallelic mutations suggesting that previous estimates may 41 42 be influenced by cryptic biallelic mutation status. While this study supports the association of single 43 PARK2 mutations with PD, it highlights confounding effects therefore caution is needed when interpreting current risk estimates. Together, we demonstrate that comprehensive assessment of 44 biallelic mutation status is essential when elucidating PD risk associated with monoallelic PARK2 45 mutations. 46

47 INTRODUCTION

Parkinson's (PD) is a multifactorial neurodegenerative disease. Common variation within 78 48 independent loci increase PD risk (1). Pathogenic mutations in autosomal dominant genes (LRRK2, 49 50 SNCA and VPS35) as well as biallelic mutations in autosomal recessive (AR) genes (PARK2, DJ-1, 51 PINK1 and FBXO7) cause Mendelian PD (2). It has been suggested that single heterozygous 52 pathogenic AR mutations can increase the risk of PD, and several lines of evidence have been provided for and against mutations (reviewed in Klein et al., 2007) (3). Previous studies may have 53 been confounded by differences in methods for mutation detection in cases and controls. Biallelic 54 AR mutations in PD genes are rare in PD cases, but single heterozygous mutations in specific AR PD 55 genes are more common and are estimated, depending on the population, to occur in between 0.6% 56 and 3% of unaffected control individuals (4-7). Accurate estimation of any risk associated with single 57 heterozygous AR mutations is therefore essential for the counselling of biallelic carriers, monoallelic 58 carriers and their family members. Furthermore, understanding the risk associated with single AR 59 mutations may provide important insights into disease biology. Here, we investigate whether single 60 carriers of disease-causing PARK2 mutations are at an increased risk for PD using three large 61 independent case-control cohorts using exome-focused genotype data, whole exome sequencing 62 and resequencing data from the International Parkinson's Disease Genomics Consortium (IPDGC). 63

64

65 **RESULTS**

We identified a total of 109 monoallelic PARK2 mutation carriers in 12,251 PD cases and controls (72 66 PD, 37 controls), carrying 19 different PARK2 variants known to cause AR PD in the biallelic state, 67 using the NeuroX genotyping platform (8). It is possible that the identified PD cases represent 68 misclassified true biallelic PARK2 PD cases. To confirm whether PD cases carry a single pathogenic 69 70 allele or whether a second variant was missed, we (i) reviewed diagnostic reports if available (n=4). or (ii) assessed available samples using multiplex ligation-dependent probe amplification (MLPA, 71 n=29). Of the 33 available NeuroX samples, representing ~30% of our putative monoallelic 72 individuals (5 controls, 13.5%; 28 PD-Monoallelic, 38.9%), six cases (18% of the available samples, 73 21% of available PD cases) were found to harbour a second mutation and therefore were removed, 74 leaving a total of 66 PD cases for all subsequent analyses (no controls were found to harbour a 75 second mutation). 76

After removal of cases with established Mendelian biallelic mutations across all known PD genes, 1.0% (66/6,552) of PD cases were found to harbour single heterozygous *PARK2* PD-causing mutations (either heterozygous copy number variants [CNVs] or single nucleotide variants [SNVs], Table 1), compared to 0.6% (37/5,693) of controls. Single heterozygote mutations might increase PD

risk (OR=1.55; 95% CI:1.03, 2.33; P=0.035), although ~70% of putative monogenic cases were not
assessed for a second mutation. If the remaining apparent monoallelic cases had a similar rate of
occult biallelic mutations, then the true underlying monoallelic carrier rate could be estimated to be
lower at 0.9%, and there would be no difference between cases and controls (OR=1.39; 95% CI:0.90,
2.16; P=0.117). Using age at onset (AAO) data from 5,710 (87.1%) cases, we found that NeuroX PD
cases with single *PARK2* mutations have significantly lower AAOs (Average=56.4 years) than cases
without known mutations (Average=61.4 years; Coeff=-5.04; 95% CI:-8.32, -1.71; P=0.003).

We next sought to explore the potential increased risk in two independent IPDGC case-control 88 cohorts, using exome sequencing (cases=1,235; controls=473) (8) and resequencing data 89 90 (cases=3,071; controls=2,162). We identified 28 (23 cases, 5 controls) and 52 (36 cases, 16 controls) carriers of single PARK2 mutations in the exome (as previously described (8)) and resequencing data 91 respectively. CNVs were not determined in the primary exome or resequencing dataset. In the 92 exome cohort, 1.9% (23/1,231) of cases and 1.1% (5/473) of controls, and in the resequencing 93 94 cohort, 1.2% (36/3,071) of cases and 0.7% (16/2,162) of controls harboured single PARK2 SNVs. 95 Before searching for occult second mutations, a meta-analysis of the three IPDGC (NeuroX, exome 96 sequencing and resequencing) cohorts revealed a significant ~1.5-fold increased risk (OR=1.57; 95% 97 Cl:1.15, 2.16; P=0.005; I²=0.0%, P_{het}=0.960) associated with PARK2 mutations (Figure 1). AAO data was available on 1,130 PD exome cases (91.8%) and 2,599 resequencing cases (84.6%). Albeit non-98 significant, exome PD cases carrying single PARK2 SNVs had lower AAO compared non-carriers 99 (Average=38.5 years vs. 43.1 years; Coeff=-4.34; 95% Cl:-8.95, 0.28; P=0.066), with carriers having 100 significantly lower AAO in resequencing cases (Average=52.6 years vs. 60.5 years; Coeff=--7.84; 95% 101 CI:-12.59, -3.09; P=0.001). We then used MLPA to search for potentially missed PARK2 CNVs in 102 mutation carriers. Four of the nine available exome DNA samples (44%, all PD cases) were found to 103 harbour a missed second mutation and were removed from subsequent analyses. Assuming a similar 104 rate of occult biallelic carriage across both datasets, the true rate of monoallelic cases could be 105 estimated to be 1.2% and 0.7% in the exome and resequencing cases as compared with 1.1% and 106 0.7% of controls, respectively. 107

We next performed a meta-analysis of available cohorts and studies that reported heterozygous PDcausing mutation rates in cases and controls, from European ancestry cohorts only. Three cohorts (Parkinson's Progression Markers Initiative, PPMI, https://www.ppmi-info.org/; UK Biobank Genotyping and Exome cohorts, https://www.ukbiobank.ac.uk/) and 21 published studies were included in our analyses (5,6,9–27). Including our cohorts, the meta-analysis revealed a significant 1.65-fold increased PD risk in single *PARK2* mutation carriers (95% CI: 1.36, 2.00; P=3.69E-07; P=0.0%, P_w=0.594) (Figure 2).

As in our study, occult second mutations are likely biasing these estimates, so we therefore restricted our meta-analysis to 9 studies (9/21, 43%) that searched for a second *PARK2* mutation (Supplementary Table 1). Based on these studies, single *PARK2* mutations confer a 2-fold increase in PD risk in carriers (OR=2.00, 95% CI:1.10, 3.62, P=0.023; I^{*} =1.3%, P_{bet}=0.423) (Supplementary Figure 1).

Inclusion of studies that used predominantly early-onset PD (EOPD) cases may additionally be inflating these estimates, we therefore repeated the meta-analysis excluding these EOPD studies (15/21, 71%), which demonstrated a 1.5-fold significant increased risk in carriers (OR=1.50, 95% Cl:1.22, 1.84; P=1.05E-04; $l^2=0\%$, $P_{tet}=0.927$) (Supplementary Figure 2).

Restricting our analysis to the four non-EOPD studies that searched for biallelic carriers demonstrated that single *PARK2* mutations were not associated with an increased PD risk in these cohorts (OR=1.23, 95% CI:0.55, 2.75, P=0.614; F=0.0%, $P_{W}=0.657$; Supplementary Figure 3).

The pathogenicity of the common *PARK2* p.R275W variant in AR PD is not as clear cut as other *PARK2* mutations. To test whether the observed SNV association is driven by p.R275W, we repeated the meta-analysis after excluding this variant. Removal of p.R275W resulted in a marginally increased estimate (OR=1.76, 95% CI:1.37, 2.28, P=1.42E-05; I²=0.0%, P_{int}=0.673; Supplementary Table 2; Supplementary Figure 4). Limiting our analysis to the 8 cohorts which assessed biallelic mutations indicated a >2-fold increased risk (OR=2.41, 95% CI:1.17, 4.96, P=0.017; I²=0.0%, P_{int}=0.791) (Supplementary Figure 5).

The contribution of biallelic *PARK2* CNVs to AR PD is well established; however, that of heterozygous CNV carriers remains unclear. We identified monoallelic *PARK2* CNVs in 0.17% (11/6,552) of non-Mendelian PD cases compared to 0.07% (4/5,693) controls (Table 1) using the NeuroX data only. None of these CNV carriers overlapped with NeuroX SNV carriers. There was a >2.5-fold increase in PD risk for *PARK2* CNV heterozygote carriers compared to controls (OR=2.53; 95% CI:0.80, 7.99; P=0.113) but this was not statistically significant.

140 It has been suggested that monoallelic PARK2 CNVs might confer a higher risk that is associated with a more pathogenic profile compared to other AR mutations (28). To assess this, we compared 141 differences in risk between CNV and SNVs carriers in the NeuroX cohort. A total of 55 PARK2 SNV 142 carriers were seen in non-Mendelian PD cases (55/6,552; 0.8%) compared to 33 controls (33/5,693; 143 0.6%) (OR=1.43; 95% CI:0.92, 2.21; P=0.108) (Table 1). To test whether PARK2 CNVs confer a more 144 "pathogenic" risk profile compared to SNVs we performed AAO analysis in the NeuroX data only. 145 Carriers of heterozygous PARK2 CNVs had a mean AAO of 58.4 years, compared to non-carriers (61.4 146 years) (Coeff=-3.11; 95% CI:-11.15, 4.93; P=0.449). 147

To further investigate the potential different risk profiles, we performed separate meta-analyses of 148 published PARK2 mutation data for SNVs and CNVs. Meta-analyses, including the current data, 149 revealed significant independent increased PD risks for SNVs (OR=1.56, 95% CI:1.22, 2.00, P=4.46E-150 04; l^{*}=0%, P_{wi}=0.968) and CNVs (OR=1.85, 95% Cl:1.38, 2.50, P=4.55E-05; l^{*}=0.0%, P_{wi}=0.640) (Figure 3; 151 Supplementary Table 3). Restricting our meta-analysis to studies that searched for second hits 152 suggested that PD risk was larger in carriers of single PARK2 CNVs (OR=3.11, 95% CI:1.23, 7.89, 153 P=0.016; I=0.0%, P_==0.879) compared to those harbouring heterozygous SNVs (OR=1.59, 95% 154 CI:0.79, 3.20, P=0.191; I²=0.0%, P_{int}=0.785). 155

156

157 DISCUSSION

The role of rare biallelic mutations in PARK2 in AR PD (MIM#600116) is well established. Here, using 158 data from a large PD case-control cohort, we identified a total of 109 carriers of single heterozygous 159 PARK2 mutations. After exclusion of PD cases with known mutations, we demonstrated that carriers 160 of single mutations were at a small but significantly increased risk of PD (OR=1.55; 95% CI:1.03, 2.33; 161 P=0.035). This was confirmed by a meta-analysis with two additional IPDGC cohorts (cases=10,954; 162 controls=8,328) which demonstrated a significant >1.5-fold increased risk (P=0.005). Carriers also 163 164 had significantly lower AAOs than non-carriers (56.4 years vs. 61.4 years; P=0.003). Similar findings were seen in the exome and resequencing data for increased risk (Exome, OR=2.20; Resequencing, 165 OR=1.59) and younger AAOs compared to non-carriers (Exome, 38.5 years vs. 43.1 years; 166 Resequencing, 52.6 years vs. 60.5 years). A meta-analysis of 19,574 PD cases and 468,488 controls 167 from 27 cohorts further confirmed that heterozygous PARK2 mutations confer an increased PD risk 168 (OR=1.65; P=3.69E-07). However, several confounding factors are likely biasing these estimates in 169 favour of increased risk and are explored below. Large-scale studies in systematically recruited 170 cohorts that have comprehensively interrogated biallelic PARK2 mutations are therefore needed to 171 accurately determine the risk associated with single mutations. 172

The relatively common p.R275W (c.823C>T, rs34424986) variant, the most frequent PD-associated 173 variant in PARK2, has not been reported in the homozygous state and has only been reported in 174 compound heterozygotes with another mutation in multiple AR PD families (MIM#602544), and has 175 been classified as likely pathogenic. p.R275W reduces protein stability by disrupting binding to 176 phosphorylated ubiquitin and results in reduced Parkin levels (29) supporting the pathogenicity of 177 p.R275W. We examined whether the increased PD risk associated with single PARK2 variants was 178 driven by this variant. The observation that the OR increases after removal suggests that p.R275W 179 may have reduced effect on enzyme activity compared to other mutations, and that, due to its more 180

common frequency, its presence may be diluting the true effect of heterozygous *PARK2* mutations in
 PD biology.

Our analysis provides some support for a more "pathogenic" risk profile associated with PARK2 CNVs 183 as compared with SNVs (CNVs, OR=2.53; SNVs, OR=1.43) in the NeuroX data. Both mutation types 184 appear to be associated with lower AAOs; however, the small number of observed CNVs prevents 185 any definitive conclusions from being drawn. While the meta-analysis results here support the 186 increased risk for PARK2 CNV carriers (OR=1.85), albeit marginally higher than PARK2 SNVs 187 (OR=1.56), the increased risk associated with PARK2 CNVs should be interpreted with care. Small 188 sample sizes, low CNV frequency and failure to investigate/report CNVs may have resulted in an 189 190 underestimated effect size seen in the meta-analysis. Failure to conclusively look for second PARK2 hits may also be a potential confounder when trying to estimate the risk associated with single 191 PARK2 mutations. Additional work in larger cohorts where both PARK2 SNVs and CNVs are routinely 192 assessed is therefore needed to gain more accurate insight into the different risk profiles associated 193 194 with different mutation types.

This large study builds on previous work looking at single PARK2 mutations in PD aetiology. While 195 196 several failed to identify single known pathogenic PARK2 mutations in controls thereby supporting 197 increased disease risk, others have found equal frequencies in both cases and controls providing evidence against increased risk (4,7,9,10,24,30-32). These estimates have, however, been based on 198 relatively small sample sets which have made it difficult to conclusively determine if single mutations 199 confer any risk. The inclusion of non-ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) variants 200 represents a potential confounder in that we may be overestimating the frequency of disease 201 relevant single PARK2 mutations. Limiting our analyses to ClinVar variants only did not result in 202 considerably different risk estimates across all comparisons (All studies, OR=1.70, P=2.65E-07; 203 Biallelic studies, OR=1.99, P=0.036; non-EOPD studies, OR=1.55, P=5.6E-05). Another confounder 204 relates to the fact that we observed a significant rate of occult second pathogenic mutations in 205 putative monoallelic cases in our NeuroX cohort. The detected rate of occult biallelic carrier status 206 was high in our two datasets (6/28, 21% and 4/9, 44%), approaching one half of PD cases with 207 apparent monoallelic status. Additionally, several studies included in the analyses here have not 208 searched for potentially hidden biallelic mutations in all cases and controls or have only interrogated 209 a subset of PARK2 mutations. Inclusion of these PD cases in our analysis is likely to appreciably 210 influence our estimate. However, restricting the meta-analyses to 9 cohorts that searched for 211 biallelic PARK2 mutations in all cases and controls demonstrated that single mutations confer a 2-212 fold increase in risk in carriers. A further confounding factor is the use of EOPD cases (<50 years) in 213 such studies which may be additionally inflating risk estimates as PARK2 mutations are more likely to 214

occur in PD cases of younger onset. This was observed in the IPDGC cohorts, with a higher estimate 215 in the exome cohort compared to the NeuroX and resequencing cohorts. The additional removal of 216 predominantly EOPD studies resulted in the loss of the original association (OR=1.23; P=0.614) but 217 this was based on a few small studies (n=4). This suggests that current estimates of the effect of 218 single mutations in modulating PD risk may not be accurate, but also stresses the importance of 219 comprehensively searching for biallelic mutations in systematically recruited cohorts. It remains 220 possible that there are further "occult" non-coding mutations affecting the promotor or splicing that 221 have not yet been identified. 222

There are some limitations to our study. NeuroX biallelic cases will have been missed as not all 223 224 possible PD-causing variants are represented on the chip (33). The same applies to the detection of biallelic carriers in the UK Biobank genotyping cohort. Identifying PARK2 CNVs from NeuroX SNP 225 genotype data using PennCNV may have missed smaller deletions/duplications. The false positive 226 rate of PennCNV as a method for CNV detection was estimated to be 9.0-17.7%, with false positive 227 228 CNVs predominantly small in size and occurring regardless of genotyping chip used (34). Our CNV detection false-positive rate in the NeuroX cohort is 6.9%. However, the fact that (i) the NeuroX 229 230 variants are not evenly distributed across the PARK2 locus (accounts for four misclassified samples), 231 and (ii) we were looking for CNVs as small as a single exon, may have resulted in our approach missing or inaccurately calling CNVs in our large cohort comprising predominantly late-onset PD 232 cases. There are limitations in defining CNVs from IPDGC and UK Biobank exome data, so CNVs were 233 only investigated using MLPA in identified PD-Monoallelic exome cases. As the exome cohort 234 predominantly consists of EOPD cases, it is likely that additional PARK2 CNVs carriers were 235 undetected. We therefore sought to validate the monoallelic status of available carriers by accessing 236 diagnostic reports or directly assessing CNVs using MLPA and discovered a high rate of undetected 237 second hits in both our datasets. Previous studies which have not systematically searched for second 238 hits may have therefore erroneously determined the monoallelic carrier rate meaning that the 239 240 estimates derived from our in-house cohorts and other published meta-analyses may not be accurate. It is therefore very important that any proposed increased risk associated with single 241 PARK2 mutations be considered with caution as, based on findings presented here, a substantial part 242 of the reported excess on monoallelic carriers may relate to occult biallelic status. 243

In conclusion, while much of the data demonstrates that harbouring a single heterozygous *PARK2* mutation increases PD risk and that single *PARK2* CNVs may be more pathogenic than *PARK2* SNVs, there may be confounding factors. This is supported by our finding of no increased risk associated with single *PARK2* mutations upon restricting our analysis to studies that assessed biallelic mutations in cases and controls, and studies that did not include predominantly EOPD cases. Before the risk

associated with single heterozygous mutations can be accurately defined, we highlight the importance of assessing 'second hits' in all cases and controls where both SNVs and CNVs are systematically interrogated in large-scale cohorts that have been systematically recruited.

252

253 METHODS AND MATERIALS

High-quality genotype data from the NeuroX chip on 6,558 PD cases and 5,693 controls was assessed 254 as part of the IPDGC (dbGaP Study Accession number: phs000918.v1.p1). Sample collection and 255 variant genotyping have been described elsewhere (33). IPDGC exome sequencing data from 1,235 256 PD cases and 473 controls were used as a replication cohort (EGA Study Accession numbers: 257 258 EGAS00001002103, EGAS00001002110, EGAS00001002113, EGAS00001002156; dbGaP Study Accession number: phs001103.v1.p1), and is described elsewhere (8). Additional replication cohorts 259 used include: IPDGC resequencing cohort (cases=3,071, controls=2,162), UK Biobank Genotyping 260 (cases=1,428, controls=312,098; downloaded April 2018, under application number 33601) and UK 261 262 Biobank exome sequencing (cases=114, controls=38,263; downloaded May 2019) cohorts and the PPMI Exome sequencing *de novo* cohort (cases=385, controls=179). Duplicate samples were 263 removed, where possible, from all analyses. Samples with missing call rates >5% were excluded 264 265 during quality control. Variants (excluding synonymous) from known Mendelian PD-causing genes were extracted. Pathogenic mutations were identified as previously described (8). Rare PARK2 266 (NM 013988 and NM 004562) CNVs were identified in the NeuroX cohort using PennCNV (34). 267 CNVs spanning a minimum of ten variants were selected and visually confirmed. Monoallelic PD 268 cases were defined as those carrying a single heterozygous pathogenic PARK2 allele as defined 269 according to OMIM (http://omim.org/), the Movement Disorder Society Genetic mutation database 270 (https://www.mdsgene.org/) or the Parkinson Disease Mutation Database (http://www.molgen.vib-271 ua.be/PDMutDB/) (Supplementary Table 4). Where available, samples were investigated by (i) 272 accessing sample diagnostic records, or (ii) using MLPA (SALSA P051 v.D1 probe mix [MRC-Holland, 273 274 The Netherlands]) to confirm their monoallelic status. Without phasing information, any two PDcausing hits identified in an individual are assumed to be in trans. 275

To assess whether PD risk might be associated with (i) all monoallelic variants, (ii) CNVs alone or (iii) SNVs alone, as indicated by case-control differences, we used logistic regression correcting for gender and principal components (C1-4). Linear regression was used to investigate the impact of single AR mutations on AAO.

A literature review was undertaken (on 01/10/2019) to identify published data on heterozygous PARK2 mutations, using search terms including combinations of the following terms: Parkinson's disease, PD, Parkin, PARK2 and heterozygous. Additional studies were identified by manual search of

references cited in published articles. Should any of the studies include previously published data, the most recent data was selected where possible. Meta-analysis was conducted using standard methods modelling fixed effects, using Cochran's Q-statistic to test for heterogeneity (P_{het}) (35) and the l² statistic (36) to quantify the proportion of the total variation caused by heterogeneity relating to possible differences in sample recruitment and assessment between studies. Meta-analyses were performed for CNVs and SNVs separately to investigate potential different risk profiles for each mutation type.

290

291 **ACKNOWLEDGEMENTS**

We would like to thank all of the subjects who donated their time and biological samples to be a part of this study. We also would like to thank all members of the International Parkinson Disease Genomics Consortium (IPDGC). See for a complete overview of members, acknowledgements and funding http://pdgenetics.org/partners.

This study was supported by Parkinson's UK (grants 8047 and J-0804) and the Medical Research 296 Council (G0700943 and G1100643). This work was supported in part by the Intramural Research 297 Programs of the National Institute of Neurological Disorders and Stroke (NINDS), the National 298 Institute on Aging (NIA), and the National Institute of Environmental Health Sciences both part of the 299 National Institutes of Health, Department of Health and Human Services; project numbers 1ZIA-300 NS003154, Z01-AG000949-02 and Z01-ES101986. This research has been conducted using the UK 301 Biobank Resource. In addition, this work was supported by the Department of Defense (award 302 W81XWH-09-2-0128), and The Michael J Fox Foundation for Parkinson's Research. This work was 303 supported by National Institutes of Health grants R01NS037167, R01CA141668, P50NS071674, 304 American Parkinson Disease Association (APDA); Barnes Jewish Hospital Foundation; Greater St Louis 305 Chapter of the APDA. The KORA (Cooperative Research in the Region of Augsburg) research platform 306 was started and financed by the Forschungszentrum für Umwelt und Gesundheit, which is funded by 307 the German Federal Ministry of Education, Science, Research, and Technology and by the State of 308 Bavaria. This study was also funded by the German Federal Ministry of Education and Research 309 310 (BMBF) under the funding code 031A430A, the EU Joint Programme - Neurodegenerative Diseases Research (JPND) project under the aegis of JPND -www.jpnd.eu- through Germany, BMBF, funding 311 312 code 01ED1406 and iMed - the Helmholtz Initiative on Personalized Medicine. This study is funded by the German National Foundation grant (DFG SH599/6-1) (grant to M.S), Michael J Fox Foundation, 313 and MSA Coalition, USA (to M.S). The French GWAS work was supported by the French National 314 Agency of Research (ANR-08-MNP-012). This study was also funded by France-Parkinson Association, 315 Fondation de France, the French program "Investissements d'avenir" funding (ANR-10-IAIHU-06) and 316

a grant from Assistance Publique-Hôpitaux de Paris (PHRC, AOR-08010) for the French clinical data. 317 This study was also sponsored by the Landspitali University Hospital Research Fund (grant to SSv); 318 Icelandic Research Council (grant to SSv); and European Community Framework Programme 7, 319 People Programme, and IAPP on novel genetic and phenotypic markers of Parkinson's disease and 320 Essential Tremor (MarkMD), contract number PIAP-GA-2008-230596 MarkMD (to HP and JHu). 321 Institutional research funding IUT20-46 was received of the Estonian Ministry of Education and 322 Research (SK). The McGill study was funded by the Michael J. Fox Foundation and the Canadian 323 Consortium on Neurodegeneration in Aging (CCNA). This study utilized the high-performance 324 computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, 325 326 Md. (http://biowulf.nih.gov), and DNA panels, samples, and clinical data from the National Institute of Neurological Disorders and Stroke Human Genetics Resource Center DNA and Cell Line 327 Repository. People who contributed samples are acknowledged in descriptions of every panel on the 328 repository website. We thank the French Parkinson's Disease Genetics Study Group and the Drug 329 330 Interaction with genes (DIGPD) study group: Y Agid, M Anheim, F Artaud, A-M Bonnet, C Bonnet, F Bourdain, J-P Brandel, C Brefel-Courbon, M Borg, A Brice, E Broussolle, F Cormier-Dequaire, J-C 331 332 Corvol, P Damier, B Debilly, B Degos, P Derkinderen, A Destée, A Dürr, F Durif, A Elbaz, D Grabli, A 333 Hartmann, S Klebe, P. Krack, J Kraemmer, S Leder, S Lesage, R Levy, E Lohmann, L Lacomblez, G Mangone, L-L Mariani, A-R Marques, M Martinez, V Mesnage, J Muellner, F Ory-Magne, F Pico, V 334 Planté-Bordeneuve, P Pollak, O Rascol, K Tahiri, F Tison, C Tranchant, E Roze, M Tir, M Vérin, F 335 Viallet, M Vidailhet, A You. We also thank the members of the French 3C Consortium: A Alpérovitch, 336 C Berr, C Tzourio, and P Amouyel for allowing us to use part of the 3C cohort, and D Zelenika for 337 support in generating the genome-wide molecular data. We thank P Tienari (Molecular Neurology 338 Programme, Biomedicum, University of Helsinki), T Peuralinna (Department of Neurology, Helsinki 339 University Central Hospital), L Myllykangas (Folkhalsan Institute of Genetics and Department of 340 Pathology, University of Helsinki), and R Sulkava (Department of Public Health and General Practice 341 Division of Geriatrics, University of Eastern Finland) for the Finnish controls (Vantaa85+ GWAS data). 342 We used genome-wide association data generated by the Wellcome Trust Case-Control Consortium 343 2 (WTCCC2) from UK patients with Parkinson's disease and UK control individuals from the 1958 344 Birth Cohort and National Blood Service. Genotyping of UK replication cases on ImmunoChip was 345 part of the WTCCC2 project, which was funded by the Wellcome Trust (083948/Z/07/Z). UK 346 population control data was made available through WTCCC1. This study was supported by the 347 Medical Research Council and Wellcome Trust disease centre (grant WT089698/Z/09/Z to NW, JHa, 348 and ASc). As with previous IPDGC efforts, this study makes use of data generated by the Wellcome 349 Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of 350

the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome 351 Trust under award 076113, 085475 and 090355. Sequencing and genotyping done in McGill 352 University was supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on 353 Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to 354 McGill University for the Healthy Brains for Healthy Lives (HBHL) program and Parkinson's Society 355 Canada. We thank Jeffrey Barrett and Jason Downing (Illumina Inc) for assistance with the design of 356 the ImmunoChip and NeuroX arrays. DNA extraction work that was done in the UK was undertaken 357 at University College London Hospitals, University College London, who received a proportion of 358 funding from the Department of Health's National Institute for Health Research Biomedical Research 359 360 Centres funding. This study was supported in part by the Wellcome Trust/Medical Research Council Joint Call in Neurodegeneration award (WT089698) to the Parkinson's Disease Consortium (UKPDC), 361 whose members are from the UCL Institute of Neurology, University of Sheffield, and the Medical 362 Research Council Protein Phosphorylation Unit at the University of Dundee. We thank the Quebec 363 364 Parkinson's Network (http://rpq-gpn.org) and its members. This work was supported by the Medical Research Council grant MR/N026004/1. The Braineac project was supported by the MRC through the 365 366 MRC Sudden Death Brain Bank Grant (MR/G0901254) to J.H. P.A.L. was supported by the MRC 367 (grants MR/N026004/1 and MR/L010933/1) and Michael J. Fox Foundation for Parkinson's Research. This work was supported by the Simpson Querrey Center for Neurogenetics (to DK). 368

369

370 CONFLICT OF INTEREST STATEMENT

371

H.R.M reports grants from Medical Research Council UK, grants from Wellcome Trust, grants from 372 Parkinson's UK, grants from Ipsen Fund, during the conduct of the study; grants from Motor Neuron 373 Disease Association, grants from Welsh Assembly Government, personal fees from Teva, personal 374 fees from Abbvie, personal fees from Teva, personal fees from UCB, personal fees from Boerhinger-375 Ingelheim, personal fees from GSK, outside the submitted work. D.K. is the Founder and Scientific 376 Advisory Board Chair of Lysosomal Therapeutics Inc. D.K. serves on the scientific advisory boards of 377 378 The Silverstein Foundation, Intellia Therapeutics, and Prevail Therapeutics and is a Venture Partner at OrbiMed. 379

380

381 **REFERENCES**

Nalls, M. A., Blauwendraat, C., Vallerga, C. L., et al. (2019) Identification of novel risk loci,
 causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide
 association studies. *Lancet Neurol.*, **18**, 1091–1102.

13

385 386	2.	Lubbe, S. and Morris, H. R. (2014) Recent advances in Parkinson's disease genetics. <i>J. Neurol.</i> , 261 , 259–66.
387 388	3.	Klein, C., Lohmann-Hedrich, K., Rogaeva, E., et al. (2007) Deciphering the role of heterozygous mutations in genes associated with parkinsonism. <i>Lancet Neurol.</i> , 6 , 652–662.
389 390	4.	Kay, D. M., Moran, D., Moses, L., et al. (2007) Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. <i>Ann. Neurol.</i> , 61 , 47–54.
391 392	5.	Kay, D. M., Stevens, C. F., Hamza, T. H., et al. (2010) A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. <i>Neurology</i> , 75 , 1189–1194.
393 394	6.	Lincoln, S. J., Maraganore, D. M., Lesnick, T. G., et al. (2003) Parkin variants in North American Parkinson's disease: Cases and controls. <i>Mov. Disord.</i> , 18 , 1306–1311.
395 396 397	7.	Brüggemann, N., Mitterer, M., Lanthaler, A. J., et al. (2009) Frequency of heterozygous Parkin mutations in healthy subjects: Need for careful prospective follow-up examination of mutation carriers. <i>Park. Relat. Disord.</i> , 15 , 425–429.
398 399 400	8.	Lubbe, S. J., Escott-Price, V., Gibbs, J. R., et al. (2016) Additional rare variant analysis in Parkinson's disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance. <i>Hum. Mol. Genet.</i> , 25 , 5483–5489.
401 402	9.	Kann, M., Jacobs, H., Mohrmann, K., et al. (2002) Role of parkin mutations in 111 community- based patients with early-onset parkinsonism. <i>Ann. Neurol.</i> , 51 , 621–625.
403 404	10.	Klein, C., Djarmati, A., Hedrich, K., et al. (2005) PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. <i>Eur. J. Hum. Genet.</i> , 13 , 1086–93.
405 406	11.	Lesage, S., Lohmann, E., Tison, F., et al. (2008) Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. <i>J. Med. Genet.</i> , 45 , 43–46.
407 408	12.	Macedo, M. G., Verbaan, D., Fang, Y., et al. (2009) Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. <i>Mov. Disord.</i> , 24 , 196–203.
409 410 411	13.	Moura, K. C. V., Campos Junior, M., De Rosso, A. L. Z., et al. (2013) Genetic analysis of PARK2 and PINK1 genes in Brazilian patients with early-onset Parkinson's disease. <i>Dis. Markers</i> , 35 , 181–185.
412 413	14.	Pankratz, N., Dumitriu, A., Hetrick, K. N., et al. (2011) Copy number variation in familial Parkinson disease. <i>PLoS One</i> , 6 , e20988.
414 415	15.	Schlitter, A. M., Kurz, M., Larsen, J. P., et al. (2006) Parkin gene variations in late-onset Parkinson's disease: Comparison between Norwegian and German cohorts. <i>Acta Neurol.</i>

416		Scand., 113 , 9–13.
417	16.	Simon-Sanchez, J., Scholz, S., Matarin, M. del M., et al. (2008) Genomewide SNP assay reveals
418		mutations underlying Parkinson disease. <i>Hum. Mutat.</i> , 29 , 315–22.
419	17.	Sironi, F., Primignani, P., Zini, M., et al. (2008) Parkin analysis in early onset Parkinson's
420		disease. Parkinsonism Relat. Disord., 14 , 326–333.
421	18.	Spataro, N., Roca-Umbert, A., Cervera-Carles, L., et al. (2017) Detection of genomic
422		rearrangements from targeted resequencing data in Parkinson's disease patients. Mov.
423		Disord., 32 , 165–169.
424	19.	Bandrés-Ciga, S., Mencacci, N. E., Durán, R., et al. (2015) Analysis of the genetic variability in
425		Parkinson's disease from Southern Spain. <i>Neurobiol. Aging</i> , 37 , 210.e1-210.e5.
426	20.	Wiley, J., Lynch, T., Lincoln, S., et al. (2004) Parkinson's disease in Ireland: Clinical
427		presentation and genetic heterogeneity in patients with parkin mutations. <i>Mov. Disord.</i> , 19 ,
428		677–681.
429	21.	Benitez, B. A., Davis, A. A., Jin, S. C., et al. (2016) Resequencing analysis of five Mendelian
430		genes and the top genes from genome-wide association studies in Parkinson's Disease. <i>Mol.</i>
431		Neurodegener., 11 , 29.
432	22.	Bras, J., Guerreiro, R., Ribeiro, M., et al. (2008) Analysis of Parkinson disease patients from
433		Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. BMC Neurol., 8, 1.
434	23.	Brooks, J., Ding, J., Simon-Sanchez, J., et al. (2009) Parkin and PINK1 mutations in early-onset
435		Parkinson's disease: comprehensive screening in publicly available cases and control. J. Med.
436		Genet., 46 , 375–381.
437	24.	Clark, L. N., Afridi, S., Karlins, E., et al. (2006) Case-control study of the parkin gene in early-
438		onset Parkinson disease. <i>Arch. Neurol.</i> , 63 , 548–52.
439	25.	Erer, S., Egeli, U., Zarifoglu, M., et al. (2016) Mutation analysis of the PARKIN, PINK1, DJ1, and
440		SNCA genes in Turkish early-onset Parkinson's patients and genotype-phenotype correlations.
441		Clin. Neurol. Neurosurg., 148 , 147–53.
442	26.	Hertz, J. M., Ostergaard, K., Juncker, I., et al. (2006) Low frequency of Parkin, Tyrosine
443		Hydroxylase, and GTP Cyclohydrolase I gene mutations in a Danish population of early-onset
444		Parkinson's Disease. <i>Eur. J. Neurol.</i> , 13 , 385–90.
445	27.	Huttenlocher, J., Stefansson, H., Steinberg, S., et al. (2015) Heterozygote carriers for CNVs in
446		PARK2 are at increased risk of Parkinson's disease. <i>Hum. Mol. Genet.</i> , 24 , 5637–5643.

447	28.	Pankratz, N., Kissell, D. K., Pauciulo, M. W., et al. (2009) Parkin dosage mutations have greater	
448		pathogenicity in familial PD than simple sequence mutations. <i>Neurology</i> , 73 , 279–286.	
449	29.	Yi, W., MacDougall, E. J., Tang, M. Y., et al. (2019) The landscape of Parkin variants reveals	
450		pathogenic mechanisms and therapeutic targets in Parkinson's disease. Hum. Mol. Genet., 28,	
451		2811–2825.	
452	30.	Hedrich, K., Marder, K., Harris, J., et al. (2002) Evaluation of 50 probands with early-onset	
453		Parkinson's disease for Parkin mutations. <i>Neurology</i> , 58 , 1239–1246.	
454	31.	West, A., Periquet, M., Lincoln, S., et al. (2002) Complex relationship between Parkin	
455		mutations and Parkinson disease. Am. J. Med. Genet Neuropsychiatr. Genet., 114 , 584–591.	
456	32.	Sun, M., Latourelle, J. C., Wooten, G. F., et al. (2006) Influence of heterozygosity for parkin	
457		mutation on onset age in familial Parkinson disease: the GenePD study. Arch. Neurol., 63,	
458		826–832.	
459	33.	Nalls, M. a, Bras, J., Hernandez, D. G., et al. (2014) NeuroX, a fast and efficient genotyping	
460		platform for investigation of neurodegenerative diseases. <i>Neurobiol. Aging</i> , 1–6.	
461	34.	Wang, K., Li, M., Hadley, D., et al. (2007) PennCNV: An integrated hidden Markov model	
462		designed for high-resolution copy number variation detection in whole-genome SNP	
463		genotyping data. <i>Genome Res.</i> , 17 , 1665–1674.	
464	35.	Petitti, D. B. (1994) Meta-analysis, Decision Analysis and Cost-Effectiveness Analysis. <i>Meta-</i>	
465		analysis, Decision Analysis and Cost-Effectiveness Analysis; Oxford University Press, New York,	
466		(1994).	
467	36.	Higgins, J. P. T. and Thompson, S. G. (2002) Quantifying heterogeneity in a meta-analysis.	
468		Stat. Med., 21 , 1539–58.	
469			
470	LEGENDS TO TABLES		
471	Table 1: Parkinson's risk profiles associated with single heterozygous PARK2 mutations.		

472 **LEGENDS TO FIGURES**

Figure 1: Forest plot of the odds ratio (OR) of the Parkinson's risk associated with heterozygous

474 PARK2 mutations in three independent International Parkinson's disease Genomics Consortium

475 (IPDGC) cohorts.

- Figure 2: Forest plot of the odds ratio (OR) of the Parkinson's risk associated with heterozygous
- 477 PARK2 mutations.
- Figure 3: Forest plot of the odds ratio (OR) of the Parkinson's risk associated with heterozygous
- 479 PARK2 single nucleotide variant (SNV) and copy number variant (CNV) carriers.

TABLES

Type	N (Freq)				ΔΔΟ	Coeff (95% CI)	P
1,100	Controls	PD		log	,,,,,		' reg
All							
With	37 (0.6%)	66 (1.0%)	1 55 (1 02 0 20)	0.025	56.4	E 04 (9 24 1 7E)	0 002
Without	5,656	6,486	1.55 (1.05, 2.52)	0.035	61.4	-5.04 (-8.34, -1.75)	0.003
CNV							
With	4 (0.1%)	11 (0.2%)		0 11 2	58.4	2 11 / 11 15 / 02)	0.440
Without	5,689	6,541	2.55 (0.80, 7.99)	0.115	61.4	-5.11 (-11.15, 4.95)	0.449
SNV							
With	33 (0.6%)	55 (0.8%)	1 42 (0 02 2 21)	0 109	56.0	E 41 (0 02 1 81)	0.002
Without	5,660	6,497	1.45 (0.92, 2.21)	0.108	61.4	-3.41 (-3.02, -1.01)	0.003

Table 1: NeuroX Parkinson's risk profiles associated with single heterozygous PARK2 mutations.

Key: AAO, age at onset; CI, confidence interval; CNV, copy number variant; Coeff, linear regression coefficient correcting for gender and principal components 1-4; Freq, frequency; N, number of samples; OR, odds ratio correcting for gender and principal components 1-4; *PARK2, Parkin* (NM_013988 and NM_004562); PD, Parkinson's cases; SNV, single nucleotide variant.

FIGURES



Figure 1: Forest plot of the odds ratio (OR) of the Parkinson's risk associated with heterozygous *PARK2* mutations in three independent International Parkinson's disease Genomics Consortium (IPDGC) cohorts.

Boxes denote OR point estimates, their areas proportional to the inverse variance weight of the estimate. Horizontal lines represent 95% CIs. Vertical dashed line represents pooled OR point estimates. Key: CI, confidence intervals; *PARK2*, *Parkin* (NM_013988 and NM_004562); %, percentage; Reseq, resequencing.

study		OR (95% CI)	% Weight
Bandres-Ciga et al. 2016 Benitez et al. 2016 Bras et al. 2008 Brooks et al. 2009 Clark et al. 2009 Clark et al. 2006 Hertz et al. 2016 Hertz et al. 2006 Huttenlocher et al. 2015 Kann et al. 2002 Kay et al. 2010 Klein et al. 2003 Lesage et al. 2008 Lincoln et al. 2003 Macedo et al. 2009 Moura et al. 2013 Pankratz et al. 2011 Schlitter et al. 2006@ Simon-Sanchez et al. 2008 Sironi et al. 2008 Spataro et al. 2017 Wiley et al. 2004 PPMI UKBiobank (Genotype) UKBiobank (Exome) Lubbe et al. (this study, Reseq) Overall (I-squared = 0.0%, p = 0.594)		$\begin{array}{c} 2.33 \ (0.09, 57.84) \\ 1.08 \ (0.18, 6.49) \\ 20.51 \ (1.09, 387.54) \\ 2.02 \ (0.67, 6.12) \\ 12.15 \ (0.66, 222.68) \\ 4.90 \ (0.23, 104.71) \\ 6.73 \ (0.36, 124.37) \\ 1.69 \ (1.11, 2.59) \\ 9.67 \ (0.54, 174.31) \\ 1.11 \ (0.54, 2.29) \\ 4.82 \ (0.19, 120.27) \\ 21.52 \ (1.24, 372.96) \\ 0.92 \ (0.32, 2.62) \\ 22.78 \ (1.25, 414.34) \\ 7.51 \ (0.36, 157.65) \\ 2.75 \ (1.08, 7.01) \\ 4.80 \ (0.19, 118.98) \\ 0.76 \ (0.17, 3.41) \\ 4.16 \ (0.23, 76.62) \\ 2.40 \ (0.27, 21.68) \\ 5.19 \ (0.28, 95.82) \\ 4.23 \ (0.23, 79.08) \\ 1.29 \ (0.77, 2.15) \\ 0.72 \ (0.10, 5.14) \\ 1.78 \ (0.67, 4.72) \\ 1.53 \ (1.02, 2.29) \\ 1.59 \ (0.88, 2.87) \\ 1.65 \ (1.36, 2.00) \\ \end{array}$	$\begin{array}{c} 0.36\\ 1.15\\ 0.43\\ 3.03\\ 0.44\\ 0.40\\ 0.44\\ 20.46\\ 0.44\\ 7.06\\ 0.36\\ 0.46\\ 3.37\\ 0.44\\ 0.40\\ 4.22\\ 0.36\\ 1.64\\ 0.40\\ 4.22\\ 0.36\\ 1.64\\ 0.43\\ 14.26\\ 0.96\\ 3.92\\ 22.73\\ 10.61\\ 100.00\\ \end{array}$
0.1	0.5 1 2 4		

Figure 2: Forest plot of the odds ratio (OR) of the Parkinson's risk associated with heterozygous *PARK2* mutations.

Boxes denote OR point estimates, their areas proportional to the inverse variance weight of the estimate. Horizontal lines represent 95% CIs. Vertical dashed line represents pooled OR point estimates. Key: CI, confidence intervals; *PARK2*, *Parkin* (NM_013988 and NM_004562); %, percentage; ^{*}German samples only.

study		OR (95% CI)	% Weight
Heterozygous PARK2 SNVs Bandres-Ciga et al. 2016 Benitez et al. 2016 Bras et al. 2008 Brooks et al. 2009 Clark et al. 2006 Erer et al. 2016 Hertz et al. 2006 Kann et al. 2007 Klein et al. 2002 Klein et al. 2008 Lincoln et al. 2003 Macedo et al. 2009 Moura et al. 2013 Schlitter et al. 2006 [®] Sironi et al. 2008 Spataro et al. 2017 Wiley et al. 2004 PPMI UKBiobank (Genotype) UKBiobank (Exome) Lubbe et al. (this study, Exome) Lubbe et al. (this study, Reseq) Subtotal (I-squared = 0.0%, p = 0.968)		$\begin{array}{c} 2.33 & (0.09, 57.84) \\ 1.08 & (0.18, 6.49) \\ 6.49 & (0.26, 161.65) \\ 1.13 & (0.16, 8.10) \\ 7.57 & (0.39, 148.52) \\ 4.90 & (0.23, 104.71) \\ 1.75 & (0.07, 43.81) \\ 5.06 & (0.26, 99.36) \\ 4.82 & (0.19, 120.27) \\ 9.87 & (0.53, 184.77) \\ 0.86 & (0.27, 2.74) \\ 10.18 & (0.49, 213.21) \\ 7.51 & (0.36, 157.65) \\ 4.80 & (0.19, 118.98) \\ 1.85 & (0.09, 39.20) \\ 2.40 & (0.27, 21.68) \\ 3.23 & (0.16, 63.91) \\ 4.23 & (0.23, 79.08) \\ 1.29 & (0.77, 2.15) \\ 0.72 & (0.10, 5.14) \\ 1.78 & (0.67, 4.72) \\ 1.45 & (0.94, 2.24) \\ 1.59 & (0.88, 2.87) \\ 1.56 & (1.22, 1.99) \\ \end{array}$	$\begin{array}{c} 0.59\\ 1.90\\ 0.59\\ 1.58\\ 0.70\\ 0.64\\ 0.59\\ 0.70\\ 0.59\\ 0.70\\ 0.59\\ 0.71\\ 4.53\\ 0.66\\ 0.59\\ 0.66\\ 1.25\\ 0.70\\ 0.71\\ 23.50\\ 1.58\\ 6.46\\ 32.62\\ 17.48\\ 100.00 \end{array}$
Heterozygous <i>PARK2</i> CNVs Bras et al. 2008 Brooks et al. 2009 Clark et al. 2006 Hertz et al. 2006 Huttenlocher et al. 2015 Kann et al. 2002 Kay et al. 2010 Lesage et al. 2008 Lincoln et al. 2003 Macedo et al. 2009 Pankratz et al. 2011 Simon-Sanchez et al. 2008 Sironi et al. 2004 Wiley et al. 2004 Lubbe et al. (this study, NeuroX) Subtotal (I-squared = 0.0%, p = 0.640)		$\begin{array}{c} 15.67 \ (0.80, \ 308.48) \\ 2.62 \ (0.67, \ 10.25) \\ 5.36 \ (0.25, \ 112.94) \\ 5.51 \ (0.29, \ 104.49) \\ 1.69 \ (1.11, \ 2.59) \\ 5.06 \ (0.26, \ 99.36) \\ 1.11 \ (0.54, \ 2.29) \\ 12.14 \ (0.67, \ 221.33) \\ 1.24 \ (0.11, \ 13.73) \\ 14.34 \ (0.74, \ 279.03) \\ 2.75 \ (1.08, \ 7.01) \\ 0.76 \ (0.17, \ 3.41) \\ 2.61 \ (0.13, \ 51.40) \\ 2.29 \ (0.11, \ 48.60) \\ 2.39 \ (0.76, \ 7.52) \\ 1.85 \ (1.38, \ 2.49) \end{array}$	$\begin{array}{c} 1.00\\ 4.72\\ 0.95\\ 1.02\\ 48.49\\ 1.00\\ 16.72\\ 1.05\\ 1.52\\ 1.00\\ 10.02\\ 3.88\\ 1.00\\ 0.95\\ 6.70\\ 100.00\\ \end{array}$
0	.1 0.5 1 2 4		

Figure 3: Forest plot of the odds ratio (OR) of the Parkinson's risk associated with heterozygous *PARK2* single nucleotide variant (SNV) and copy number variant (CNV) carriers.

Boxes denote OR point estimates, their areas proportional to the inverse variance weight of the estimate. Horizontal lines represent 95% Cls. Vertical dashed line represents pooled OR point estimates. Key: Cl, confidence intervals; IPDGC, International Parkinson's disease Genomics Consortium; *PARK2*, *Parkin* (NM_013988 and NM_004562); %, percentage; PPMI, Parkinson's Progression Markers Initiative; Reseq, Resequencing; ^{*}German samples only.

ABBREVIATIONS

%	Percent
AAO	Age at onset
AR	Autosomal recessive
с.	coding DNA reference sequence
C1-4	Principal component 1 to 4
CI	Confidence interval
CNV	Copy number variant
Coeff	β-Coefficient
dbGaP	Database of Genotypes and Phenotypes
DNA	Deoxyribonucleic acid
EGA	European Genome-phenome Archive
EOPD	Early-onset Parkinson's
FBXO7	F-box protein 7
Freq	Frequency
l ²	Proportion of total variation caused by heterogeneity
IPDGC	International Parkinson's Disease Genomics Consortium
LRRK2	Leucine-rich repeat kinase 2
MLPA	Multiplex ligation-dependent probe amplification
MRC-Holland	Microbiology Research Centre Holland
Ν	Number
NM_*	Messenger RNA sequence identifier
OMIM	Online Mendelian Inheritance in Man
OR	Odds ratio
Ρ	P-value
р.	protein reference sequence
PARK2	Parkin
PARK7	Parkinsonism associated deglycase or DJ-1
PD	Parkinson's
PD-Monoallelic	Parkinson's cases harbouring a single heterozygous PARK2 mutation
P _{het}	Cochran's Q-statistic test for heterogeneity P-value
PINK1	PTEN-Induced putative kinase 1

P _{log}	Logistic regression P-value
РРМІ	Parkinson's Progression Markers Initiative
P_{reg}	Linear regression P-value
Reseq	Resequencing
SNCA	α-Synuclein
SNV	Single nucleotide variant
VPS35	Vacuolar protein sorting 35, yeast, homolog of
vs.	Versus